- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04447183
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. (DTC)
October 20, 2023 updated by: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
This is a randomized, open, parallel controlled, multi-center clinical trial; 120 subjects were randomly assigned to the test group and the control group according to 3:1.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study was conducted in patients with differentiated thyroid cancer who had undergone near-total thyroidectomy.
After surgery patients were randomized to one of two methods of performing thyroid remnant ablation (use of radioiodine to remove any remaining thyroid tissue).
One group of patients who took thyroid hormone medicine and were euthyroid [i.e.
their thyroid stimulating hormone (TSH) levels are normal], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
The second group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e.
their TSH levels were high), and were given oral radioiodine.
All patients received the same amount of radioactive iodine (30mCi±1.5mCi
or 1.11GBq of 131I).
Approximately 9 months later, whole body scans were performed on all patients to learn whether the thyroid remnants had been successfully ablated.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yansong Lin, PhD
- Phone Number: +86-010-69156114
- Email: linys@pumch.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Pathological diagnosis of differentiated thyroid cancer, including papillary thyroid cancer (including papillary carcinoma follicular subtype), follicular thyroid cancer, and Hurthle cell thyroid cancer;
- Patients who were at 18~75 years old (male or female).
- Patients with a total or near-total thyroidectomy within 12 weeks prior to enrollment and plan to performing radioactive iodine((131)Ⅰ) thyroid remnant ablation.
- Serum TSH ≤ 0.5 mU/L;
- Women of childbearing age are HCG-negative;
- Low iodine diet before enrollment for more than 4 weeks;
- Patients are voluntarily enrolled, and written informed consent forms can be used for treatment and visits as required by the program.
Exclusion Criteria:
- Any significant clinical and laboratory abnormalities (eg, severe cardiopulmonary disease, hepatic insufficiency, renal function Incomplete, congestive heart failure, advanced lung disease or advanced cardiovascular and cerebrovascular disease, active infection);
- Patients who have used any water-soluble radiographic contrast agent intravenously, underwent intrathecal iodine angiography or gallbladder iodine imaging within 3 months before administration;
- Taken/eaten within 4 weeks prior to administration Drugs/foods that affect iodine uptake or metabolism, such as multivitamins, glucocorticoids, diuretics, lithium, thiouracil, tazobactam, algae, iodine (except thyroid hormone replacement therapy);
- Before administration Stroke, unstable angina (CCS class II or higher), atrial fibrillation or medication (within beta blocker or digoxin) within 6 months Patients with a history of arrhythmia;
- Pregnant or lactating women;
- Patients who are allergic to rhTSH and its excipients;
- Patients with positive infection-related tests : Includes hepatitis C、syphilis and AIDS;
- Participated in any drug or medical device clinical trial within 1 month prior to the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test group
The test group of patients who took thyroid hormone medicine and were euthyroid [i.e.
their thyroid stimulating hormone (TSH) levels are normal], and received injections of Thyrogen (0.9 mg daily on two consecutive days) followed by oral radioiodine.
|
rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi
or 1.11GBq of 131I oral
Other Names:
radioactive iodine: 30mCi±1.5mCi
or 1.11GBq of 131I oral
|
Experimental: Control group
The control group of patients did not take thyroid hormone medicine so that they were hypothyroid (i.e.
their TSH levels were high,TSH≥30mU/L), and were given oral radioiodine.
|
radioactive iodine: 30mCi±1.5mCi
or 1.11GBq of 131I oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ablation success rate by Diagnostic Whole Body Scan (DxWBS)
Time Frame: at week 36
|
In the THW state (TSH≥30mU/L), DxWBS showed the proportion of subjects who did not see radioactive iodine uptake in the thyroid gland.
|
at week 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum thyroglobulin (Tg) levels
Time Frame: at week 36
|
In the THW state (TSH≥30mU/L), the proportion of patients with Tg levels <1ng/mL and neck B-ultrasound negative during rhTSH stimulation accounted for all subjects.
|
at week 36
|
Adverse Event
Time Frame: up to week 40 ± 7 day
|
Classification and degree of adverse events
|
up to week 40 ± 7 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yansong Lin, PhD, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 23, 2020
Primary Completion (Estimated)
August 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
June 23, 2020
First Submitted That Met QC Criteria
June 24, 2020
First Posted (Actual)
June 25, 2020
Study Record Updates
Last Update Posted (Actual)
October 23, 2023
Last Update Submitted That Met QC Criteria
October 20, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Thyroid Diseases
- Thyroid Neoplasms
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Trace Elements
- Micronutrients
- Iodine
- Hormones
Other Study ID Numbers
- ZGTSH002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Differentiated Thyroid Cancer
-
Thomas Jefferson UniversityActive, not recruitingDifferentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
National Cancer Institute (NCI)TerminatedThyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
Children's Hospital of PhiladelphiaBayerRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
Istituti Clinici Scientifici Maugeri SpAMerck Sharp & Dohme LLCRecruiting
-
National Taiwan University HospitalRecruitingDifferentiated Thyroid CancerTaiwan
-
Genzyme, a Sanofi CompanyCompletedEvaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (VERIFY)Differentiated Thyroid CancerUnited States, Sweden, Brazil, Italy, Poland, Spain, China, Russian Federation, France, Japan, Denmark, Czechia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdTerminatedDifferentiated Thyroid CancerChina
-
AstraZenecaTerminatedDifferentiated Thyroid CancerUnited States, Denmark, Italy, Sweden, Poland, Brazil, France, Germany
Clinical Trials on Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedDifferentiated Thyroid CancerChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingDifferentiated Thyroid CancerChina
-
University College, LondonActive, not recruitingHead and Neck CancerUnited Kingdom
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Zensun Sci. & Tech. Co., Ltd.Recruiting
-
Peking University Third HospitalRecruiting
-
Bharat Serums and Vaccines LimitedActive, not recruitingFemale InfertilityIndia
-
Zensun Sci. & Tech. Co., Ltd.Active, not recruitingChronic Systolic Heart FailureChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.UnknownChronic Renal Failure With HemodialysisChina